Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Meagan Montesion

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

M. Montesion1, C.H. Chung2, E.S. Sokol3, S.A. Khan4, H. Kang5, L.A. Albacker1, J.M. Johnson6, G.M. Frampton1, V.A. Miller7, J.S. Ross8, S.M. Ali7

Author affiliations

  • 1 Cancer Genomics Research, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 2 Department Of Head And Neck-endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa/US
  • 3 Cancer Genomics Research, Foundation Medicine, Inc., Cambridge/US
  • 4 Department Of Internal Medicine, University of Texas Southwestern Medical Center, Dallas/US
  • 5 Department Of Oncology, Johns Hopkins University School of Medicine, 21231 - Baltimore/US
  • 6 Department Of Medical Oncology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 7 Clinical Development, Foundation Medicine, Inc., Cambridge/US
  • 8 Pathology, Foundation Medicine Inc., Cambridge/US
More

Resources

Abstract 3574

Background

Squamous cell carcinomas (SCC) have diverse anatomic etiologies but may share common genomic biomarkers. We profiled 7,871 unique SCCs across nine anatomic sites to investigate commonality in genomic alterations (GA), tumor mutational burden (TMB), human papillomavirus (HPV) association, and mutational signatures.

Methods

Tissue from over 8,100 unique SCC samples originating from nine anatomic sites (anogenital (anus, cervix, penis, vagina, vulva), esophagus, head and neck, lung, and skin) were sequenced by hybrid capture-based comprehensive genomic profiling to evaluate GA and TMB. About 3% of non-cutaneous SCC samples had UV signatures, indicative of potential primary site misdiagnoses, and were filtered from the analysis. Detection of HPV, including high-risk strains 16, 18, 31, 33, and 45, was implemented through de novo assembly of non-human sequencing reads and BLASTn comparison against all viral nucleotide sequences in the NCBI database.

Results

The proportion of HPV+ patients by anatomic site varied, with the highest being anal (91%) and cervical (83%). The mutational landscape of each cohort was similar, regardless of anatomic origin, but clustered based on HPV status. The largest differences in GA frequency as stratified by HPV- vs. HPV+ were TP53 (87% vs. 12%), CDKN2A (45% vs. 6%), and PIK3CA (22% vs. 33%). The median TMB in cases originating from HPV-associated sites was similar, regardless of HPV status. Higher median TMB was observed in lung and skin cases, which exhibited significant enrichment of mutational signatures indicative of tobacco- and UV-induced DNA damage, respectively.

Conclusions

HPV+ and HPV- SCC populations have distinct genomic profiles and, for the latter, anatomic site is correlated with TMB distribution, secondary to associated carcinogen exposure. As such, biomarkers such as TMB and UV signature can provide unexpected insight into site of origin misdiagnoses and may correlate with benefit from immune checkpoint inhibitors.Table: 68P

Tumor Site% HPV+Median TMB (Interquartile Range)% TMB  > = 10% TMB  > = 20
Anogenital (n = 1213)765 (6)175
Head and Neck (n = 1843)364 (5)155
Esophageal (n = 416)65 (4)132
Lung (n = 3977)59 (8)439
Skin (n = 422)840 (69)6862

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc.

Funding

Foundation Medicine, Inc.

Editorial Acknowledgement

Disclosure

M. Montesion, E.S. Sokol: Employee: Foundation Medicine, Inc. L.A. Albacker, G.M. Frampton, V.A. Miller, J.S. Ross, S.M. Ali: Employee and stock ownership: Foundation Medicine, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings